Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3239905 trials

Vaxcell-Bio Therapeutics

Official website

Vaxcell-Bio develops Vax-NK/Vax-CAR cancer immunotherapies, veterinary drug Baxrukin-15, and pet supplements Goldmune and Bakshure.

As of 2026-10-11, Vaxcell-Bio Therapeutics has 21 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Vaxcell-Bio Therapeutics was founded in 2010 and listed on KOSDAQ in 2020 as a cancer immunotherapy developer. Its pipeline includes the Vax-NK natural killer cell therapy platform, the Vax-CAR platform (CAR-MIL, CAR-T), the veterinary immunotherapy Baxrukin-15, and the pet health supplements Goldmune and Bakshure. The company completed a Phase 2a trial of Vax-NK in advanced hepatocellular carcinoma and submitted a closing report to the Ministry of Food and Drug Safety, while Baxrukin-15 is sold domestically through Yuhan Corporation and supplied overseas under agreements with VisionMed and Nubepharma.

Products & technology

  • Vax-NK cancer immune cell therapyNK-cell-based cancer immunotherapy; Phase 2a completed in advanced hepatocellular carcinoma
  • Vax-CAR (CAR-MIL, CAR-T)CAR-MIL for multiple myeloma and dual-antigen-targeting CAR-T for solid tumors, preclinical
  • CAR-NK therapyFor autoimmune disease, co-developed with BioDesignLab and Samsung Medical Center
  • Small-molecule targeted anticancer agent (MYO1D)First-in-class agent degrading MYO1D to degrade growth factor receptors
  • Bispecific antibody therapy (nanobody)Nanobody-based bispecific antibody for solid tumors
  • Baxrukin-15Veterinary prescription drug for post-surgical mammary tumor immunotherapy and combination therapy for canine lymphoma
  • GoldmunePet immune supplement containing fucoidan, Sparassis crispa, and goat milk
  • BakshureNew immune supplement containing beta-glucan

Clinical trials

data.go.kr

5 MFDS clinical trial authorisations · 2013–2019 (Phase 2a 2 · Phase 1 2 · Phase 2 1)

  • Phase 2aVax-DC/MM2019-04-05

    1 trial site

  • Phase 2aVax-NK/HCC2018-05-30

    5 trial sites

  • Phase 2Vax-DC/MM2017-08-14

    1 trial site

  • Phase 1Vax-NK/HCC2016-01-12

    1 trial site

  • Phase 1Vax-DC/MM2013-10-16

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

Vax-NK · 진행성 간세포암 · 임상 2a상 완료 · Closing report submitted to Ministry of Food and Drug Safety

Vax-NK · 소세포폐암(확장병기) · 첨단재생의료 임상연구 · Subject enrollment completed November 2025; results report in progress

Vax-NK · 췌장암 · 첨단재생의료 임상연구 · Clinical study initiated July 2025, ongoing

CAR-MIL · 다발골수종 · 전임상

CAR-T · 고형암 · 전임상 · Dual-antigen targeting

CAR-NK · 자가면역질환 · Co-developed with BioDesignLab and Samsung Medical Center

저분자화합물 표적항암제(MYO1D) · First-in-class development degrading growth factor receptors via MYO1D degradation

이중항체 치료제 · 고형암 · 개발 중 · Nanobody structure

DDS/제제 플랫폼 · 황반변성 등 · Platform acquired via merger with AL Biotech; completed formulations licensed to pharmaceutical companies

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 11 more publications

Patents

KIPRIS · applicant-matched
Show 6 more patents

AI reads

MAA server logs · IP-verified
66
Times AI engines pulled Vaxcell-Bio Therapeutics's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

5
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

61
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 1
Last 7 days
52
live 1
Last 30 days
66
live 5
All time
  • OpenAIChatGPT-Userlive5
  • OpenAIOAI-SearchBot55
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 25, 2026 · 4 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Vaxcell-Bio Therapeutics and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition